Willis Tower 233 S. Wacker Drive, Metropolitan Club, 66th Floor, Oak Room, Chicago, Illinois 60606.

## FOR FURTHER INFORMATION CONTACT:

Andy Cebula, NAC Secretariat, (202) 330–0652, acebula@rtca.org, 1150 18 Street NW., Suite 910, Washington, DC 20036, or by fax at (202) 833–9434, or Web site at http://www.rtca.org.

SUPPLEMENTARY INFORMATION: Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.), notice is hereby given for a meeting of the Twenty Second Meeting of the NextGen Advisory Committee (NAC). The agenda will include the following:

## October 4, 2017 9:00 a.m.-2:00 p.m.

- Opening of Meeting/Introduction of NAC Members—Chairman David Bronczek
- Official Statement of Designated Federal Officer—Dan Elwell, FAA Deputy Administrator
- 3. Review and Approval of June 28, 2017 Meeting Summary and Revised Terms of Reference
- 4. Chairman's Report—Chairman Bronczek
- 5. FAA Report—FAA
- Making Single European Sky ATM Research (SESAR) a Performing Operational Reality
- Northeast Corridor Phase Two Tasking—Interim Report; Action Item: Consideration for Approval
- 8. Joint Analysis Team—Boston
  Optimized Profile Descent/
  DataComm Benefits Assessment—
  Final Report; Action Item:
  Consideration for Approval
- 9. Regional Airline Equipage
- 10. NextGen Priorities Status—NextGen Integration Working Group (NIWG): Performance Based Navigation (PBN), Data Communications, Surface Operations & Data Sharing, Multiple Runway Operations; Action Item: Consideration for Approval of 2017 NextGen Priorities Joint Implementation Plan
- 11. Equipage Status
- 12. Other business
- 13. Summary of Meeting and next steps
- 14. Closing Comments—DFO and NAC Chairman
- 15. Adjourn

Although the NAC meeting is open to the public, the meeting location has limited space and security protocols that require advanced registration. To attend: Please email bteel@rtca.org with name, company, and phone number contact to pre-register no later than September 25, 2017.

With the approval of the chairman, members of the public may present oral statements at the meeting. Persons wishing to present statements or obtain information should contact the person listed in the FOR FURTHER INFORMATION CONTACT section. Members of the public may present a written statement to the committee at any time.

Issued in Washington, DC, on September 14, 2017.

#### Mohannad Dawoud,

Management & Program Analyst, Partnership Contracts Branch, ANG–A17, NextGen, Procurement Services Division.

[FR Doc. 2017-19892 Filed 9-14-17; 4:15 pm]

BILLING CODE 4910-13-P

## **DEPARTMENT OF TRANSPORTATION**

## Federal Motor Carrier Safety Administration

[FMCSA Docket No. FMCSA-2017-0037]

## Qualification of Drivers; Exemption Applications; Diabetes Mellitus

**AGENCY:** Federal Motor Carrier Safety Administration (FMCSA), DOT.

**ACTION:** Notice of final disposition.

SUMMARY: FMCSA announces its decision to exempt 29 individuals from the prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs) against persons with insulin-treated diabetes mellitus (ITDM) from operating a commercial motor vehicle (CMV) in interstate commerce. The exemptions enable these individuals with ITDM to operate CMVs in interstate commerce.

**DATES:** The exemptions were applicable on July 7, 2017. The exemptions expire on July 7, 2019.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, Medical Programs Division, (202) 366–4001, fmcsamedical@dot.gov, FMCSA, Department of Transportation, 1200 New Jersey Avenue SE., Room W64–224, Washington, DC 20590–0001. Office hours are from 8:30 a.m. to 5 p.m., E.T., Monday through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Docket Services, telephone (202) 366–9826.

## SUPPLEMENTARY INFORMATION:

### I. Electronic Access

You may see all the comments online through the Federal Document Management System (FDMS) at: http://www.regulations.gov.

Docket: For access to the docket to read background documents or comments, go to http://www.regulations.gov and/or Room

W12–140 on the ground level of the West Building, 1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., E.T., Monday through Friday, except Federal holidays.

Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits comments from the public to better inform its rulemaking process. DOT posts these comments, without edit, including any personal information the commenter provides, to <a href="http://www.regulations.gov">http://www.regulations.gov</a>, as described in the system of records notice (DOT/ALL-14 FDMS), which can be reviewed at <a href="http://www.dot.gov/privacy">http://www.dot.gov/privacy</a>.

#### II. Background

On June 6, 2017, FMCSA published a notice announcing receipt of applications from 29 individuals requesting an exemption from diabetes requirement in 49 CFR 391.41(b)(3) and requested comments from the public (82 FR 26226). The public comment period ended on July 6, 2017, and no comments were received.

FMCSA has evaluated the eligibility of these applicants and determined that granting the exemptions to these individuals would achieve a level of safety equivalent to or greater than the level that would be achieved by complying with the current regulation 49 CFR 391.41(b)(3).

The physical qualification standard for drivers regarding diabetes found in 49 CFR 391.41(b)(3) states that a person is physically qualified to drive a CMV if that person:

Has no established medical history or clinical diagnosis of diabetes mellitus currently requiring insulin for control.

#### **III. Discussion of Comments**

FMCSA received no comments in this proceeding.

## IV. Basis for Exemption Determination

Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption from the diabetes standard in 49 CFR 391.41(b)(3) if the exemption is likely to achieve an equivalent or greater level of safety than would be achieved without the exemption. The exemption allows the applicants to operate CMVs in interstate commerce.

The Agency's decision regarding these exemption applications is based on the program eligibility criteria and an individualized assessment of information submitted by each applicant.

These 29 applicants have had ITDM over a range of 1 to 37 years. These applicants report no severe hypoglycemic reactions resulting in loss of consciousness or seizure, requiring

the assistance of another person, or resulting in impaired cognitive function that occurred without warning symptoms, in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the past five vears. In each case, an endocrinologist verified that the driver has demonstrated a willingness to properly monitor and manage his/her diabetes mellitus, received education related to diabetes management, and is on a stable insulin regimen. These drivers report no other disqualifying conditions, including diabetes related complications. Each meets the vision requirement at 49 CFR 391.41(b)(10).

The qualifications, experience, and medical condition of each applicant were stated and discussed in detail in the June 6, 2017, **Federal Register** notice (82 FR 26226) and will not be repeated in this notice.

Consequently, FMCSA finds that in each case exempting these applicants from the diabetes requirement in 49 CFR 391.41(b)(3) is likely to achieve a level of safety equal to that existing without the exemption.

### V. Conditions and Requirements

The terms and conditions of the exemption are provided to the applicants in the exemption document and includes the following: (1) Each driver must submit a quarterly monitoring checklist completed by the treating endocrinologist as well as an annual checklist with a comprehensive medical evaluation; (2) each driver must report within two business days of occurrence, all episodes of severe hypoglycemia, significant complications, or inability to manage diabetes; also, any involvement in an accident or any other adverse event in a CMV or personal vehicle, whether or not it is related to an episode of hypoglycemia; (3) each driver must provide a copy of the ophthalmologist's or optometrist's report to the Medical Examiner at the time of the annual medical examination; and (4) each driver must provide a copy of the annual medical certification to the employer for retention in the driver's qualification file, or keeping a copy in his/her driver's qualification file if he/ she is self-employed. The driver must also have a copy of the exemption when driving, for presentation to a duly authorized Federal, State, or local enforcement official.

## VI. Preemption

During the period the exemption is in effect, no State shall enforce any law or regulation that conflicts with this exemption with respect to a person operating under the exemption.

### VII. Conclusion

Based upon its evaluation of the 29 exemption applications, FMCSA exempts the following drivers from the diabetes requirement in 49 CFR 391.41(b)(10), subject to the requirements cited above:

Tyler J. Bren (ND)

Charlie H. Brown, Jr. (GA)

Ajax A. Castro (FL)

Robert J. Conklin (PA)

Luke S. Davidson (CA)

Joseph R. DePra (IN)

Joseph P. Finan (RI)

Luis Garcia (NJ)

Eric E.T. Gheen (OH)

Aron A. Hanson (IL)

Tyler J. Hanson (ID)

Antonio K. Hoes (MD)

Ronald O. Knighten (WA)

Stephen P. Koons (PA)

Angel Luna (PA)

David Mills (NH)

Kenneth J. Moe (MN)

James L. Pearson (NY)

Walter R. Rentsch (SD)

Richard D. Revere (PA)

Redmond L. Riley (NC)

James H. Roth, Jr. (PA)

Stephen R. Shaffer (KS)

Matthew J. Thornton (OR)

Michael H. Trayah (VT)

William Wagstaff, 3rd (MD)

Craig A. Wildenberg (WI)

Ronald E. Wulf (MN)

Samuel K. Zeweldie (GA)

In accordance with 49 U.S.C. 31136(e) and 31315, each exemption will be valid for two years from the effective date unless revoked earlier by FMCSA. The exemption will be revoked if the following occurs: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained prior to being granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315.

Issued on: September 13, 2017.

## Larry W. Minor,

Associate Administrator for Policy. [FR Doc. 2017–19907 Filed 9–18–17; 8:45 am]

BILLING CODE 4910-EX-P

### **DEPARTMENT OF TRANSPORTATION**

# Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2006-26367]

# Medical Review Board (MRB) Meeting: Public Meeting

**AGENCY:** Federal Motor Carrier Safety Administration (FMCSA), DOT.

**ACTION:** Announcement of advisory committee public meeting.

**SUMMARY:** FMCSA announces a meeting of its Medical Review Board (MRB) on Tuesday and Wednesday, September 26-27, 2017. The MRB will make recommendations to the Agency on the revision of the Agency's handbook for medical examiners (ME) who are on the National Registry of Certified Medical Examiners (National Registry), for their use in evaluating interstate commercial motor vehicle (CMV) drivers for a medical qualification determination. Additionally, the MRB will review the Agency's current advisory and exemption program criteria concerning individuals taking anti-seizure medication and identify factors the Agency should consider for potential regulatory actions that would eliminate the need for granting exemptions. The meeting is open to the public for its entirety. The public will be allowed to comment during the proceedings.

DATES: The meeting will be held on Tuesday and Wednesday, September 26–27, 2017, from 9:15 a.m. to 4:30 p.m., Eastern Daylight Time (E.T.), at the FMCSA National Training Center, 1310 N. Courthouse Road, Arlington, VA, 6th Floor. Copies of the task statement and an agenda for the entire meeting will be made available in advance of the meeting at www.fmcsa.dot.gov/mrb.

FOR FURTHER INFORMATION CONTACT: Ms. Shannon L. Watson, Senior Advisor to the Associate Administrator for Policy, Federal Motor Carrier Safety Administration, U.S. Department of Transportation, 1200 New Jersey Avenue SE., Washington, DC 20590, (202) 366–5221, mrb@dot.gov.

## Services for Individuals With Disabilities

For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact Eran Segev at (617) 494–3174, eran.segev@dot.gov, by Wednesday, September 20.

## SUPPLEMENTARY INFORMATION: